iMDx’s GraftAssure Assay Gains Momentum with Real-World Data Presentations
Event summary
- iMDx to present real-world data on GraftAssure assay at three international conferences in April and June 2026.
- Company reports unaudited Q1 2026 cash balance of $29.4 million, in line with guidance.
- GraftAssureDx submitted for FDA regulatory review on March 25, 2026, following Class II de novo pathway.
- iMDx to host fireside chat at Needham Virtual Healthcare Conference on April 15, 2026.
- Company recognized $32,000 in laboratory services revenue in Q1 2026, remains pre-revenue for diagnostic test kits.
The big picture
iMDx is positioning GraftAssure as a disruptive technology in the $2 billion addressable market for kitted transplant rejection testing. The company's strategy of enabling localized testing aims to improve access and turnaround times for kidney transplant patients. The upcoming data presentations and FDA submission mark critical milestones in iMDx's journey to commercialize its flagship assay.
What we're watching
- Regulatory Pathway
- Whether the FDA's review of GraftAssureDx will proceed smoothly under the Class II de novo pathway.
- Commercial Momentum
- The pace at which iMDx can transition from pre-revenue to commercial sales of its diagnostic test kits.
- Clinical Adoption
- How the GALACTIC registry study will influence the adoption of GraftAssure in the transplant community.
Related topics